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Abstract
Giant cell tumor of bone (GCTB) is mostly a benign disease of the bone, although
with high local recurrence rate and potential formetastatic spread, namely to the lungs.
It is also a locally aggressive tumor, associated with severe morbidity and functional
impairment due to bone destruction. Treatment is therefore required and should be
offered at an early stage to allow complete resection, minimizing functional sequelae
and local recurrence. Surgical resection is themainstay of treatment, often followed by
intralesional adjuvant therapy. GCTB has a particular biology, in which RANKL repre-
sents a key factor in tumor pathogenesis, thusmaking this molecule a valuable thera-
peutic target. Monthly administration of denosumab, a fully humanmonoclonal
antibodydirected against RANKL, has been studied in several clinical trials and shown a
high rate of local control with favorable safety profile. In this chapter, current medical
management, ongoing studies, and future directions in GCTBwill be discussed.
Keywords: denosumab, giant cell tumor of bone, RANKL, sarcoma,
sarcomatoid transformation
1. Introduction
Giant cell tumor of bone (GCTB) is a primary tumor of bone usually arising in
the meta-epiphysis of long bones, although potentially also occur in other parts of
the skeleton, such as the spine or pelvis [1]. GCTBmore often affects young patients
in the second to forth decades of life [1, 2] and those living in urban (rather than
rural) areas [3]. It is also associated with Paget’s disease [4]. The condition presents
with localized pain, tenderness to touch, palpable mass, and decreased range of
motion, as well as mechanical pain and joint swelling in patients with presentation
near joints [5]. Rarely, it may present with pathological fracture [4].
GCTB is mostly a benign disease, but local recurrence rates are high and there is
a small risk of metastatic spread, namely to the lungs [1, 6]. Risk factors for
pulmonary metastases include young age, Enneking stage 3, local recurrence, and
axial disease, but not treatment modality [6, 7]. Pulmonary metastases most often
appear three to four years after initial diagnosis and rarely are the cause of death
[8]. However, when GCTB metastasizes, mortality rate rises to 14–25% [8, 9].
Despite being a rare event, GCTB can also undergo malignant sarcomatoid
transformation [10]. In these cases, malignant GCTB can present with three histo-
logic subtypes: osteosarcoma, fibrosarcoma, or undifferentiated pleomorphic
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sarcoma. This usually occurs following multiple recurrent lesions (e.g. Paget’s dis-
ease) and/or radiation therapy [5].
MulticentricGCTB in another rare formof tumor presentation, characterized by two
ormore distant lesions of histologically confirmeddisease [11]. These lesions canpresent
as synchronous (more common) ormetachronous. Althoughmulticentric GCTB
appears to have demographic differences (patients are young andmore commonly
female), disease behavior including local recurrence rates, pulmonarymetastases
pattern, andmalignant transformation seems to be similar to solitary GCTB [11].
Radiologically, GCTB presents as an osteolytic lesion with characteristic radiolu-
cent and geographic (well-circumscribed) appearance and fading cortical bone,
rarely showing periosteal reaction. GCTBs are usually eccentric masses in the epiph-
yseal region extending to subchondral bone (sclerotic metaphyseal margin) [5, 12].
Besides a high degree of suspicion in radiological exams (plain films, computed
tomography [CT], and magnetic resonance imaging [MRI]), GCTB diagnosis must
be histologically confirmed by core-needle or open biopsy [5]. Still, plain radio-
graphs, CT scan, and MRI are useful for diagnosis and local staging. MRI is often
performed to delineate neoplasm extent, namely soft tissue extension. Additionally,
bone scintigraphy helps ruling out other asymptomatic bone lesions and chest CT
scan should be performed to exclude lung involvement and guide treatment.
Based on radiological findings and according to Enneking and later Campanacci
grading systems, GCTB can be classified in three grades [7, 13]:
• Grade I (latent): well-defined margin (thin rim of mature bone) and intact
cortex (not deformed).
• Grade II (active): relatively well-defined margins but no radiopaque rim;
cortex is thinned and moderately expanded. Grade II lesions with fracture are
graded separately.
• Grade II (aggressive): indistinct borders and cortex destruction, suggesting
rapid and permeated growth.
This surgical staging system allows preoperative planning. Post-operatively,
GCTB can also be graded based on histological features in grade 1 (typical), grade 2
(aggressive), or grade 3 (malignant) [14].
Due to lack of long-term follow-up data, GCTB prognosis is not well established to
date [15]. However, the overall prognosis of benignGCTB is generally favorable. Recur-
rence rates are estimated at 25%[15] and canbe as high as 50%after curettage alone [16].
Systemic treatment with bisphosphonates or denosumab seems to lower these figures
[17]. Although secondary lung involvement is rare in benign GCTB and very uncom-
monly the cause of death, mortality rate is higher in these patients (14–25%) [8, 9, 18].
Regardingmalignant GCTB (either primary or secondary), overall survival at 5 years is
about 85% and poorest in older patients and those with distant disease at diagnosis,
according to a Surveillance, Epidemiology and End Results (SEER) study involving 117
cases of malignant GCTB [19]. Smaller studies may indicate worse survival rates [20].
2. GCTB biology and pathogenesis
2.1 Histopathology
GCTB is histologically characterized by diffuse growth of receptor activator of
nuclear factor kappa-B ligand (RANKL)-positive, round-to-oval polygonal or
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elongated mononuclear stromal cells, RANK-positive mononuclear cells of myeloid
linage, and RANK-positive osteoclast-like giant cells, reflecting a physiopathology
intimately linked to the RANKL/RANK pathway [17, 21, 22] (Figure 1). Small areas
of osteoid matrix deposition, woven bone, and occasionally new bone are also
observed in about 50% of GCTB samples, with different studies reporting an
incidence between 22 and 52% [23].
The characteristic giant cells in GCTB are osteoclastic in nature [24–28] and
represent the reactive component responsible for GCTB aggressive lytic behavior,
leading to GCTB designation as osteoclastoma. These cells express RANK but not
RANKL [26]. Profiling studies have shown that giant cells in GCTB are the result of
CD33+ pre-osteoclast fusion that further fuse with CD14+ mononuclear cells [27]
and express tartrate-resistant acid phosphatase (TRAP) and vitronectin receptor,
osteoclast markers, being capable of lacunar resorption [29].
However, in GCTB neoplastic cells are ovoid stromal cells, displaying markers of
mesenchymal stem cells derived from the osteoblast lineage, but minimal expres-
sion of fully differentiated osteoblasts, like osteocalcin, alkaline phosphatase,
osteoprotegerin (OPG), and TRAIL [29–33]. Twist-mediated downregulation of
RUNX2, a major osteogenic regulator, has been shown to interrupt osteoblastic
differentiation and depress osteoblast lineage markers in GCTB [34].
GCTB stromal cells express high levels of RANKL [27] and also produce other
osteoclastogenic cytokines, like interleukin (IL)-1, 6, 11, and  17, tumor
necrosis factor-alpha (TNF-α), and macrophage colony-stimulating factor (M-
CSF), through which osteoclast differentiation is stimulated from precursor cells
[26]. Other characteristics supporting their neoplastic nature include dominance,
increased proliferative potential, abundance of genetic alterations, and expression
of more differentiation markers than multinucleated giant cells [22]. GCTBs are
polyclonal in nature, with inconsistent chromosomal changes and telomere associa-
tions occurring in up to 72% of cases, although lacking prognostic value [35–38].
Mononuclear stromal cell-exclusive mutation p.G34W (or p.G34L, p.G34M, p.
G34R, or p.G34V in a small sub-set of cases) in the H3F3A gene, encoding histone
3.3 (H3.3) variant implicated in epigenetic reprogramming and memory, has been
identified as GCTB-specific driver mutation [30].
Because G34W mutations occur more frequently than chromosomal abnormali-
ties and can be causative risk factors for chromosomal structural remodeling in
DNA synthesis, it has been hypothesized that this driver mutation causes chromo-
somal instability and defects, contributing to pleiotropic effects on cell cycle-related
expression, immature osteoblastic differentiation, and chemokines, cytokines, and
Figure 1.
Representative images of RANKL (A) and RANK (B) immunohistochemistry in formalin-fixed and
paraffin-embedded GCTB samples. (unpublished data).
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surface markers expression [22, 37]. Additionally, mutations in cyclin D1, p53, and
MET have been linked to malignant transformation and GCTB recurrence [22].
Biologically, Wnt/β-catenin and transforming growth factor beta (TGF-β) sig-
naling pathways mediate the exacerbated proliferation of stromal cells in GCTB. β-
catenin, cyclin D1, and p21 have been shown to be overexpressed in the nuclei of
GCTB stromal cells [39]. Additionally, one study showed that protease activated
receptor-1 (PAR-1) is also upregulated in GCTB downstream of TGF-β, via Smad3
and Smad4 [40]. In the study, PAR-1 knockout in GCTB stromal cells inhibited
tumor growth, angiogenesis, and osteoclastogenesis in vitro and PAR-1 inhibition
suppressed tumor growth and giant cell formation in vivo.
2.2 Physiopathology
GCTB physiopathology is not entirely understood, but there is compelling evi-
dence that RANKL overexpression by mononuclear stromal cells plays a key role
and elicits transformation of monocytic pre-osteoclast to osteoclast cells, ultimately
resulting in osteolysis observed in these tumors [22, 41–43] (Figure 2). Accord-
ingly, preclinical models have shown that OPG, a soluble decoy receptor for
RANKL, inhibits monocyte activation and osteoclast differentiation [44].
Figure 2.
Simplified scheme of GCTB physiopathology. BMP-2, bone morphogenetic protein 2; CCR2, C-C chemokine
receptor type 2; CXCR4, C-X-C chemokine receptor type 4; DC-STAMP, dendritic cell-specific
transmembrane protein; IL-1, interleukin 1; MCP-1, monocyte chemoattractant protein-1; M-CSF,
macrophage colony-stimulating factor; MIP-1α, macrophage inflammatory protein 1-alpha; MMPs, matrix
metalloproteases; OC-STAMP, osteoclast stimulatory transmembrane protein; RANKL, receptor activator of
nuclear factor kappa-Β ligand; SDF-1, stromal cell-derived factor 1; TGF-β, transforming growth factor beta;
TNFα, tumor necrosis factor alpha; TRAP, tartrate-resistant acid phosphatase; VEGF, vascular endothelial
growth factor.
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In GCTB, stromal cell-derived monocyte chemoattractant protein-1 (MCP-1/
CCL2) recruits bone marrow-derived CCR2/CXCR4-expressing monocytic osteo-
clast precursors from peripheral blood [45, 46]. Other soluble factors within GCTB
microenvironment are chemotactic for myelomonocytic cells, including stromal
cell-derived factor 1 (SDF-1/CXCL12), macrophage inflammatory protein 1-alpha
(MIP-1α/CCL3), and M-CSF1 [26, 47]. Osteoclast precursors localized at GCTB
microenvironment differentiate into active, bone resorbing, osteoclasts.
Different pre-clinical studies have shown that GCTB stromal cells with circulat-
ing mononuclear cells co-culture induces differentiation of osteolytic giant cells
[41–43]. For differentiation to occur, RANKL expression in stromal cells is regu-
lated by CCAAT/enhancer-binding protein beta (C/EBPβ), found to be
overexpressed in GCTB [48], and also by parathyroid hormone-related peptide
(PTHrP) in an autocrine manner [49]. Next, RANKL-induced cell fusion is co-
stimulated by M-CSF and IL-34 [26] and enhanced by specific transmembrane
proteins overexpressed in GCTB [50] and coupling components, like insulin-like
growth factors (IGF) I and II [51].
RANK pathway activation in giant cells leads to up-regulation of nuclear factor
of activated T cells c1 (NFATc1), an auto-regulated key transcription factor
responsible for regulating expression of important genes involved in bone resorp-
tion, like cathepsin K or β3-integrin [52]. Cathepsin K is involved in initial steps of
bone resorption, degrading collagen type I and remodeling the bone matrix,
allowing migration. As bone resorption starts, TGF-β entrapped in bone matrix is
activated by matrix metalloproteases (MMPs), stimulating giant cell migration
[46], which is mediated by αvβ3 integrin attachment to the bone matrix [53].
MMPs have an important role in GCTB physiopathology. Apart from the above-
mentioned role in giant cell migration via TGF-β activation, MMPs influence other
major aspects within the tumor microenvironment, like angiogenesis, invasion, and
metastatic development. MMP-2 and MMP-9 are key in all these processes [22]. In
GCTB, the extracellular matrix metalloproteinase inducer (EMMPRIN) is responsi-
ble for inducing MMP expression. Higher EMMPRIN expression at multinuclear
osteoclast-like giant cells has been observed in stage III GCTB, probably regulated
by RANKL from stromal-like tumor cells [54].
As previously mentioned, metastases are extremely rare in GCTB and there are
no clues on molecular or physiopathological events related with GCTB
metastization to date.
2.3 Tumor markers
Pathophysiology of GCTB progression remains unclear and prognostic factors,
treatment targets, and predictive biomarkers represent unmet needs.
Histologically, ambiguous giant cell-rich lesions  including benign GCTB,
chondroblastoma, aneurysmal bone cyst, central giant cell granuloma of the jaw,
and malignant giant cell–rich osteosarcoma  are often found, especially as small
biopsy or curettage specimens [22]. In these cases, H3F3A gene p.G34W mutation
can be used in the differential diagnosis, as it is almost GCTB-exclusive [30, 55].
Approximately 90% of GCTBs display the p.G34W mutation, with minor subsets
(<2%) displaying p.G34L, p.G34M, p.G34R, or p.G34V variants. H3F3B p.K36M is
the H3.3 mutation found in the vast majority (90–95%) of chondroblastomas [30].
H3.3 p.G34W mutant-specific immunohistochemistry (IHC; clone RM263,
commercially available) is a highly sensitive and specific surrogate marker of
H3F3A p.G34W mutation in GCTB [56–58], being useful for practical diagnosis in
primary [58] or recurrent, metastatic, and secondary malignant GCTB [59].
Although denosumab therapy may decrease p.G34W expression [22], evidence
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shows that spindle cells and cells in and around immature bone in denosumab-
treated GCTBs are H3.3 p.G34W-positive by IHC, with H3F3A mutations consis-
tently detected in corresponding samples [56, 58, 60, 61], which may predict
relapse risk [55].
Although rare, malignant GCTB may occur, and studies suggest that p.G34W
mutation is preserved [55]. One report, however, showed loss of one H3F3A allele
(probably the mutant allele) in GCTB malignant component, leading to negative p.
G34W IHC [62].
p63, a member of the p53 family of transcription factors, has also been studied as
biomarker in GCTB diagnosis. p63 immunostaining has been used in diagnosis of
head and neck squamous cell carcinoma, prostate adenocarcinoma (negative for
p63 in opposition to p63-positive benign prostatic tissue) [63], and poorly differ-
entiated squamous cell carcinoma [64]. p63 has also been shown to be highly
expressed in GCTB mononuclear neoplastic cells [65–67], but its usefulness is still to
be determined. A meta-analysis of eight different studies including 335 GCTB
patients showed that p63 is a helpful marker for GCTB diagnosis in critically ill
patients, although it cannot be recommended as a single definitive diagnostic
marker [68].
Figure 3.
Flowchart of GCTB treatment. Adapted from NCCN guidelines – Bone cancer [73]. CT, computorized
tomography; MRI, magnetic resonance imaging; RT, radiation therapy; SC, subcutaneous.
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Finally, it has been suggested that high RANKL, IL-6, TNFα, SDF-1, and MCP-1
expression may help predict GCTB metastatic potential and prognosis, warranting
further studies [69].
3. Treatment overview
Treatment options for localized GCTB include en bloc resection or curettage with
or without local adjuvants, like phenol, liquid nitrogen, or polymethylmethacrylate
[70]. Radiation therapy (RT) can also be used as an alternative to surgery for local
control, with 5-year local control rates of 80% [71]. However, RT is associated with
risk of malignant transformation into high-grade sarcoma, making surgery the
preferred option when possible. Contrarily to palliative care in irresectable or dis-
tant disease, systemic neoadjuvant or adjuvant therapy with the RANKL-binding
fully human monoclonal antibody denosumab is still not established [70, 72].
A treatment algorithm is depicted in Figure 3.
4. Medical therapy
4.1 Denosumab
Denosumab is a fully human monoclonal antibody (IgG2) that binds with high
affinity and specificity to RANKL [74], thereby inhibiting osteoclast-mediated
osteolysis. Given GCTB pathophysiology and its association to RANKL/RANK
pathway, denosumab has proven effective in this disease.
In patients with resectable GCTB, adjuvant denosumab at a 120 mg dosage
administered subcutaneously every 28 days, with additional loading doses on days 8
and 15 on the first month, during 6 months after complete resection has been
approved by both the Food and Drug Administration and European Medicines
Agency [72, 75, 76]. However, this treatment is still debated. Studies supporting its
use in the adjuvant setting are scarce and mostly rely in level IV evidence. Con-
versely, evidence from a systematic review by Luengo-Alonso [72] favored adju-
vant denosumab, which showed a positive histological and clinical (pain relief)
response. In patients with unresectable GCTB (either primary or recurrent) or
when complete excision is possible but post-surgical severe morbidity and func-
tional impairment is expected, neoadjuvant denosumab should be started (same
dosing scheme as above) and response to treatment evaluated. Should the patient
respond to denosumab and surgery be feasible with acceptable morbidity, then
complete excision and possibly adjuvant denosumab for six months should be
considered. On the other hand, the optimal denosumab duration is still debatable
when treatment response is suboptimal or in cases of sacral or spinal GCTB, multi-
ple lesions (including pulmonary metastases), or patient’s clinical ineligibility for
surgery. Denosumab should be considered until progression or unacceptable toxic-
ity (e.g., osteonecrosis of the jaw), provided at least partial response is achieved.
4.2 Bisphosphonates
Bisphosphonates inhibit osteoclast-mediated bone resorption and are used in
cancer patients, especially in bone metastases setting. In GCTB patients, denosumab
is the preferred systemic treatment option. However, evidence regarding the use of
adjuvant denosumab is not consistent and some studies show lack of benefit in local
recurrence rates [77, 78]. Bisphosphonates, like zoledronic acid (ZA), can be an
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option in the adjuvant setting. A recent meta-analysis of case–control studies
showed that the use of adjuvant bisphosphonates in patients submitted to
intralesional curettage may decrease local recurrence rates, independently of
Campanacci staging [79]. In patients undergoing wide resection, bisphosphonates
seem to have no benefit in local recurrence. A phase II non-randomized clinical trial
of adjuvant ZA after extensive curettage in GCTB patients showed that ZA failed to
prevent local recurrence [80]. Another phase II multicentric, randomized, open-
label clinical trial showed no benefit with adjuvant ZA, although the study was
terminated earlier due to poor accrual [81]. The use of adjuvant bisphosphonates
should be evaluated on a case-by-case basis. In unresectable or metastatic GCTB,
clinical studies addressing the use of bisphosphonates are also scarce. Overall, the
role of bisphosphonates in the treatment of patients with GCTB remains to be
clearly defined.
4.3 Chemotherapy/systemic cytotoxic agents/interferon
Chemotherapy agents and interferon-α have also been used to treat GCTB, as
reported in case reports and small series, but results were poor and there are no
clinical trials to guide their use. Anecdotal small retrospective case series and case
reports have documented the use of doxorubicin [82, 83], cyclophosphamide [84],
cisplatin plus doxorubicin [85], combination therapy with vincristine, doxorubicin,
cyclophosphamide and actinomycin-D, followed by high-dose methotrexate and
vincristine [86], interferon alpha 2a [87] and interferon alpha 2b [88], with mixed
results.
5. Conclusions and future directions
GCTB is a primary and mostly benign tumor of bone usually arising in the meta-
epiphysis of long bones and more often affecting young patients. Despite its fre-
quent benign nature, local recurrence rate is high and there is a non-negligible risk
of distant metastization, namely to the lungs. Therefore, treatment should provide
the best chance of curative outcome with minimal functional sequelae and quality
of life impairment.
The main pillar of treatment is surgery, but systemic therapy has a role in
adjuvant and palliative settings. Regarding GCTB pathophysiology, RANKL/RANK
pathway is central to tumor development and denosumab, a monoclonal antibody
against RANKL, is the most studied and most effective systemic therapy for the
disease. Its use is particularly established in the palliative setting, i.e., in cases of
unresectable disease, patient ineligibility for surgery, or lung involvement.
Although less studied, bisphosphonates can also be an option. However, their role in
GCTB medical management needs to be better clarified.
GCTB rare nature, particularly malignant GCTB, hampers the development of
clinical trials to investigate new drugs for second-line treatment and establish the
optimal treatment sequence (neo- vs. adjuvant denosumab or adjuvant denosumab
vs. after recurrence, etc.). Currently, one clinical trial (NCT04255576) is studying
the use of JMT103, a novel fully human IgG4 monoclonal antibody against RANKL,
in GCTB [89]. Another clinical trial (NCT03449108) is using a different approach
to address bone tumors, including GCTB [90], by studying the use of LN-145-S1, or
autologous tumor infiltrating lymphocytes, in treatment-refractory or relapsed dis-
ease. As discussed above, mutations in cyclin D1, p53, and MET have been associ-
ated with GCTB malignant transformation and recurrence. This raises the
hypothesis that cyclin-dependent kinase (CDK) inhibitors (e.g., ribociclib,
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palbociclib) and MET inhibitors (e.g., crizotinib) may be useful in this disease.
Although these therapies have been approved in other tumors (CDK inhibitors in
breast cancer and crizotinib in lung cancer), no studies are in place in GCTB yet.
Another promising target is MMPs, specially MMP-2 and MMP-9, that play an
important role in GCTB physiopathology, namely regarding tumor microenviron-
ment, angiogenesis, invasion, and metastatic development. Preclinical studies in
breast cancer used ML115, a bone-seeking MMP inhibitor, to prevent bone metas-
tases [91], with promising results. Although still far from use in the clinical practice,
this could be another potential therapy worth studying in GCTB. Several other
clinical trials continue to investigate the use of denosumab, bisphosphonates, and
local therapy (surgery/RT) [92–97].
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Nomenclature
BMP-2 Bone morphogenetic protein 2
CCR2 C-C chemokine receptor type 2
CXCR4 C-X-C chemokine receptor type 4
C/EBPβ CCAAT/enhancer binding protein beta
CT Computorized tomography
CDK Cyclin-kinase inhibitors
DC-STAMP Dendritic cell-specific transmembrane protein
EMMPRIN Extracellular matrix metalloproteinase inducer
FFPE Formalin-Fixed Paraffin-Embedded




IGF Insulin-like growth factor
IL-1 Interleukin 1
M-CSF Macrophage colony-stimulating factor
MIP-1α Macrophage inflammatory protein 1-alpha;
MRI Magnetic resonance imaging
MMP Matrix metalloprotease
MCP-1 Monocyte chemoattractant protein-1
NFATc1 Nuclear factor of activated T cells c1
OC-STAMP Osteoclast stimulatory transmembrane protein
PTHrP Parathyroid hormone related peptide
RT Radiation therapy
RANKL Receptor activator of nuclear factor kappa-B ligand
RUNX2 Runt-related transcription factor 2
SC Subcutaneous
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SDF-1 Stromal cell-derived factor 1
TRAP Tartrate-resistant acid phosphatase
TRAIL TNF-related apoptosis inducing ligand
TGF-β Transforming growth factor beta
TNF-α Tumor necrosis factor-alpha
VEGF Vascular endothelial growth factor
ZA Zoledronic acid
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